Overview

Evaluation of the Safety of Relaxin in Preeclampsia

Status:
Suspended
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia
Phase:
Phase 1
Details
Lead Sponsor:
Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Treatments:
Methocarbamol